10-Q: SCPHARMACEUTICALS Reports Strong FUROSCIX Revenue Growth

SCPHARMACEUTICALS Inc. reported significant revenue growth for FUROSCIX in Q2 2025, driven by increased demand and expanded indications, despite continued operating losses.

Summary

• Product revenues for the three months ended June 30, 2025, increased to $16.0 million, up from $8.1 million in the same period of 2024.
• Product revenues for the six months ended June 30, 2025, rose to $27.8 million, compared to $14.2 million for the six months ended June 30, 2024.
• Net loss for the three months ended June 30, 2025, was $(18.0) million, an increase from $(17.1) million in the prior year's comparable quarter.
• Net loss for the six months ended June 30, 2025, was $(37.8) million, up from $(31.2) million for the six months ended June 30, 2024.
• The accumulated deficit reached approximately $404.3 million as of June 30, 2025.
• Cash and cash equivalents decreased to $40.8 million as of June 30, 2025, from $75.7 million at December 31, 2024.
• Approximately 20,200 FUROSCIX doses were filled in the quarter ended June 30, 2025.
• The FDA approved the supplemental drug application expanding the FUROSCIX indication to include NYHA Class IV heart failure patients on August 9, 2024.
• FDA approval for FUROSCIX for the treatment of edema in adult patients with chronic kidney disease (CKD) was received on March 6, 2025, with commercial launch commencing in April 2025.
• The company is developing an 80mg/1mL autoinjector for FUROSCIX, targeting a supplemental New Drug Application (sNDA) submission in the third quarter of 2025.
• An increase of 15-25% in cost of product revenues is anticipated in 2026 due to ongoing negotiations with the device manufacturer for the current FUROSCIX product.

Sentiment

Score: 5

Explanation: While FUROSCIX demonstrates strong revenue growth and market expansion through new indications and an upcoming autoinjector, the company continues to incur significant and increasing net losses, leading to a negative stockholders' equity. The substantial decrease in cash and reliance on future capital raises, coupled with anticipated increases in product costs, present considerable financial risks. The long-term potential is clear, but the current financial trajectory warrants caution.

Positives

• Product revenues increased by $8.0 million (98%) to $16.0 million for the three months ended June 30, 2025, compared to the same period in 2024, driven by increased demand for FUROSCIX.
• Product revenues increased by $13.6 million (96%) to $27.8 million for the six months ended June 30, 2025, compared to the same period in 2024, reflecting strong commercial launch progress.
• The FDA approved the supplemental drug application expanding the FUROSCIX indication to include NYHA Class IV heart failure patients on August 9, 2024.
• FDA approval for FUROSCIX to treat edema in adult patients with chronic kidney disease (CKD) was granted on March 6, 2025, with commercial launch initiated in April 2025, expanding the addressable market.
• The FDA awarded 3-year exclusivity to FUROSCIX on October 7, 2024, based on essential clinical investigations, protecting the product until October 7, 2025.
• Positive pharmacokinetic/pharmacodynamic (PK/PD) study data for a combination product using a lead formulation was announced in August 2024.
• Development of an 80mg/1mL autoinjector is underway, which is expected to significantly reduce manufacturing costs compared to the current on-body infusor and offer environmental advantages.
• The estimated total addressable market opportunity for FUROSCIX in the United States is $12.5 billion.
• The estimated average cost of treatment with FUROSCIX for each episode is approximately $5,685, which is significantly lower than the cost of a single hospitalization for worsening heart failure, offering potential cost savings to payers and hospitals.
• Existing cash and cash equivalents, along with funds available under the Revenue Purchase and Sale Agreement, are projected to be sufficient to meet cash commitments for at least the next 12 months.

Negatives

• Net loss increased to $(18.0) million for the three months ended June 30, 2025, from $(17.1) million in the prior year, indicating continued unprofitability.
• Net loss increased to $(37.8) million for the six months ended June 30, 2025, from $(31.2) million in the prior year, showing a worsening financial performance.
• The accumulated deficit grew to $404.3 million as of June 30, 2025.
• Cash and cash equivalents significantly decreased from $75.7 million at December 31, 2024, to $40.8 million at June 30, 2025, reflecting substantial cash burn.
• Total stockholders' equity shifted from a positive $13.3 million at December 31, 2024, to a deficit of $(21.3) million at June 30, 2025.
• An increase of 15-25% in cost of product revenues is anticipated in 2026 due to current negotiations with the device manufacturer, which could impact gross margins.
• The company has a limited operating history and limited history of commercializing pharmaceutical products, making it difficult to evaluate future success prospects.
• Heavy dependence on a limited number of specialty pharmacy customers and distributors, with three customers representing 91% of revenue for the three and six months ended June 30, 2025.
• Reliance on a limited number of suppliers and contract manufacturers for production, with two suppliers representing 44% of accounts payable at June 30, 2025, posing supply chain risks.
• Fair value adjustments to the term loan and revenue purchase and sale liability resulted in expenses of $(150) thousand and $(2,560) thousand, respectively, for the three months ended June 30, 2025.

Risks

• Heavy dependence on the success of FUROSCIX and other product candidates; no assurance of regulatory approval for any other product candidates.
• Failure to produce FUROSCIX in required volumes on a timely basis could lead to delays in commercialization efforts.
• Commercial success of FUROSCIX and any other approved product candidates depends on attaining market acceptance by hospital networks, physicians, patients, third-party payers, and the medical community.
• Inability to expand sales and marketing capabilities or enter into agreements with third parties to market and sell FUROSCIX may prevent generation of substantial revenue.
• Limited operating history and limited history of commercializing pharmaceutical products may make it difficult to evaluate prospects for future success.
• History of significant operating losses and expectation to incur significant and increasing losses for the foreseeable future; may never achieve or maintain profitability.
• Need for additional funding and potential inability to raise capital when needed, which would force delays, reductions, or elimination of product development programs or commercialization efforts.
• Success depends on the ability to manufacture, or the ability of third parties to deliver, sufficient quantities of supplies, components, and drug product at competitive costs, including monitoring quality control issues.
• Ability to protect intellectual property and proprietary technology, as well as the ability of collaborators to protect their intellectual property.
• Failure to comply with obligations under existing and future intellectual property licenses with third parties could lead to loss of important license rights.
• Potential exposure to product liability lawsuits related to approved product candidates, which could divert resources, result in substantial liabilities, and reduce commercial potential.
• Failure to successfully identify, develop, and market additional product candidates could impair the ability to grow.
• Dependence on executive officers, directors, and principal consultants; loss of their services would materially harm the business.
• Recently enacted and future legislation (e.g., ACA, IRA, OBBB Act) may increase the difficulty and cost of obtaining marketing approval, restrict post-approval activities, affect prices, and reduce Medicaid funding.
• Exposure to market risks related to changes in foreign currency exchange rates (principally Swiss franc and Euro) and interest rates.
• Fair value of liabilities related to the Credit Agreement and Revenue Purchase and Sale Agreement will increase as market interest rates decrease and may fluctuate based on the company's credit rating.
• If costs, particularly related to manufacture and supply, become subject to significant inflationary pressures, it may adversely impact the business, operating results, and financial condition.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as it supports the commercialization of FUROSCIX in the United States, expands its sales and marketing organization, and continues research and development efforts for new product candidates and enhancements. Research and development expenses are anticipated to increase in absolute dollars. Selling, general and administrative expenses are also expected to rise to support commercialization activities. The company is targeting a supplemental New Drug Application (sNDA) submission for its 80mg/1mL autoinjector in the third quarter of 2025, with an anticipated launch in late 2026. An increase of 15-25% in the cost of product revenues is expected in 2026 due to device manufacturer negotiations, though this impact is projected to be minimal beyond 2026 with the autoinjector launch. Existing cash and cash equivalents, combined with available funds from the Revenue Purchase and Sale Agreement, are deemed sufficient to meet cash commitments for at least the next 12 months, with potential for additional funding through equity or debt offerings if needed.

Management Comments

• Our strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous, or IV, delivery. By moving delivery away from the high-cost healthcare settings typically required for IV administration, we believe our strategy has the potential to reduce overall healthcare costs and advance the quality and convenience of care.
• We believe FUROSCIX will allow eligible patients with chronic heart failure and chronic kidney disease with worsening symptoms due to fluid overload despite oral diuretics to receive IV-strength diuresis outside the high-cost hospital setting.
• We believe we can drive significant cost savings to payers and hospitals and improve patients quality of life through outpatient management of their fluid overload.
• We expect to continue to incur net losses for the foreseeable future as we support the commercialization efforts of FUROSCIX in the United States, including expanding our sales and marketing organization, continuing research and development efforts, engaging in scale-up manufacturing and seeking regulatory approval for new product candidates and enhancements.

Industry Context

The company operates in the cardiorenal healthcare sector, focusing on developing and commercializing products that optimize the delivery of infused therapies through subcutaneous administration. This strategy aligns with broader industry trends towards reducing healthcare costs, improving patient convenience, and shifting care from high-cost inpatient settings to outpatient or home-based management. The development of an autoinjector for FUROSCIX further supports this trend by offering an easier, at-home administration option for chronic conditions. The market for chronic heart failure and chronic kidney disease treatments is substantial, and the company aims to capture a significant share by offering a more cost-effective and convenient alternative to traditional intravenous delivery. However, the pharmaceutical industry, including this company, faces increasing legislative and regulatory scrutiny regarding drug pricing and reimbursement, as evidenced by the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act, which could impact future revenue and profitability.

Comparison to Industry Standards

• FUROSCIX demonstrated 99.6% bioavailability (90% CI: 94.8%-104.8%) and 8-hour urine output of 2.7 L, which was similar to subjects receiving intravenous furosemide, establishing IV equivalence.
• The estimated average cost of treatment with FUROSCIX for each episode is approximately $5,685, which is stated to be significantly lower than the cost of a single hospitalization for worsening heart failure, positioning it as a cost-effective alternative to inpatient care.

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that are believed to have, individually or in the aggregate, a material adverse effect on its business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders face potential for significant dilution if additional equity is raised, and continued operating losses and a growing accumulated deficit negatively impact equity value.
• Patients benefit from expanded indications for FUROSCIX (NYHA Class IV heart failure, CKD) and the development of an autoinjector, which aim to improve patient care, convenience, and access to IV-equivalent diuresis at home.
• Payers and hospitals could realize significant cost savings as FUROSCIX aims to reduce heart failure hospital admissions and readmissions by enabling outpatient management of fluid overload.
• Employees are impacted by increased employee-related costs in R&D and SG&A, suggesting continued investment in personnel, with stock-based compensation forming part of their remuneration.
• Suppliers and manufacturers are critical, with dependence on a limited number of these entities creating supply chain risks, and ongoing negotiations with the device manufacturer expected to impact future product costs.

Next Steps

• Continue U.S. commercialization of FUROSCIX, including expanding the direct sales force.
• Continue research and development efforts, including advancing pipeline programs beyond FUROSCIX.
• Engage in scale-up manufacturing to meet demand.
• Seek regulatory approval for new product candidates and enhancements.
• Initiate preclinical testing and clinical trials for any identified product candidates.
• Identify additional research programs and product candidates.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional research, clinical, and scientific personnel.
• Targeting a supplemental New Drug Application (sNDA) submission for the 80mg/1mL autoinjector in the third quarter of 2025.
• Anticipated launch of the 80mg/1ml autoinjector in late 2026.

Key Dates

Recommendation

While FUROSCIX demonstrates strong revenue growth and market expansion with new indications and an upcoming autoinjector, the company continues to incur substantial and increasing net losses, leading to a negative stockholders' equity. The significant cash burn and reliance on future capital raises, coupled with anticipated increases in product costs, present considerable financial risks. The long-term potential is clear, but the current financial trajectory warrants caution, suggesting a 'Hold' for existing investors to monitor execution and financial stability, rather than a 'Buy' given the high risk, or a 'Sell' given the product's market traction.

Keywords

FUROSCIX, scPharmaceuticals, chronic heart failure, chronic kidney disease, edema, fluid overload, subcutaneous administration, autoinjector, pharmaceutical, FDA approval, 10-Q, revenue growth, net loss, drug development, commercialization, biotechnology